These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34954841)

  • 1. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
    Sigurgeirsson B; Browning J; Tyring S; Szepietowski JC; Rivera-Díaz R; Effendy I; Keefe D; Bruin G; Paguet B; Fu R; Hampele I; Reinhardt M; Patekar M
    Dermatol Ther; 2022 Mar; 35(3):e15285. PubMed ID: 34954841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
    Sigurgeirsson B; Schäkel K; Hong CH; Effendy I; Placek W; Rich P; Keefe D; Bruin G; Charef P; Fu R; Hampele I; Patekar M
    J Dermatolog Treat; 2022 May; 33(3):1718-1726. PubMed ID: 33896356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
    Lacour JP; Paul C; Jazayeri S; Papanastasiou P; Xu C; Nyirady J; Fox T; Papavassilis C
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):847-856. PubMed ID: 28111801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L; Zhang JZ; Yao X; Gu J; Liu QZ; Zheng M; Zhang SF; Xu JH; Li CX; Cheng H; Guo Q; Pan WL; Li SQ; Li RY; Guo ZP; Song ZQ; Li SS; Dong XQ; Wang L; Fu R; Regnault P; Charef P; Mazur R; Patekar M
    Chin Med J (Engl); 2020 Nov; 133(22):2665-2673. PubMed ID: 33060370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
    Blauvelt A; Gordon KB; Lee P; Bagel J; Sofen H; Lockshin B; Soliman AM; Geng Z; Zhan T; Alperovich G; Stein Gold L
    J Dermatolog Treat; 2022 Jun; 33(4):2085-2093. PubMed ID: 33947295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB; Kubanov A; van Doorn M; Sullivan J; Papp KA; You R; Regnault P; Frueh JA
    Br J Dermatol; 2020 Apr; 182(4):889-899. PubMed ID: 31286480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
    Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
    Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
    Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
    Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
    J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.